NCT04991766View on ClinicalTrials.gov

A Study of [¹⁴C]-LY3484356 in Healthy Female Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

April 2, 2022

Study Completion Date

April 2, 2022

Conditions
Healthy
Interventions
DRUG

[¹⁴C]-LY3484356

Administered orally.

DRUG

LY3484356

Administered orally.

DRUG

[¹⁴C]-LY3484356 (IV)

Administered IV.

Trial Locations (1)

53704

LabCorp CRU, Inc., Madison

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04991766 - A Study of [¹⁴C]-LY3484356 in Healthy Female Participants | Biotech Hunter | Biotech Hunter